Evgen Pharma plc (EVG) Ordinary 0.25p
Share news, reports & tips
13 June 2019 09:03
(Sharecast News) - Evgen Pharma on Thursday reported a slightly widened annual loss due to a cost increase, with its results in line with expectations as its drugs remain in the development stage.
25 March 2019 09:27
(Sharecast News) - Clinical stage drug development company Evgen Pharma announced positive headline results from the open-label phase 2 trial of 'SFX-01' in 46 patients with estrogen-positive...
12 December 2018 10:10
(Sharecast News) - Evgen Pharma's shares stumbled on Wednesday after its interim loss before tax expanded, though the company was "delighted" by progress in treatment developments.
11 September 2018 12:51
(Sharecast News) - JD Wetherspoons: Berenberg upgrades to buy with a target price of 1,450p.
27 July 2018 13:14
(Sharecast News) - William Hill: Peel Hunt upgrades to hold with a target price of 305p.
25 July 2018 14:48
(Sharecast News) - Clinical-stage drug development company Evgen Pharma has concluded patient recruitment in its STEM Phase IIa trial of SFX-01 in metastatic breast cancer, it announced on Wednesday.
25 July 2018 13:57
(Sharecast News) - Unite Group: Numis downgrades to hold with a target price of 900p.
13 June 2018 08:33
(Sharecast News) - Tate & Lyle: Jefferies downgrades to hold with a target price of 700p.
11 June 2018 14:47
(Sharecast News) - Clinical stage drug development company Evgen Pharma announced an encouraging interim update on STEM, its Phase II clinical trial in advanced breast cancer, on Monday.
11 June 2018 12:46
(Sharecast News) - Rio Tinto: Deutsche Bank downgrades to hold with a target price of 4,700p.
25 April 2018 12:46
(WebFG News) - CityFibre: RBC Capital Markets downgrades to sector perform with a target price of 81p.
11 December 2017 13:17
(ShareCast News) - Virtual pharmaceutical company Evgen announced on Monday that it was progressing in Phase II clinical trials of SFX-01 for both subarachnoid haemorrhage and ER+ breast cancer, with...
Company announcements Announcements
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see http://www.DigitalLook.com/newsfeedterms for our terms and conditions.
© Digital Look Ltd 1998-2019. All rights reserved.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.